The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Drug repositioning and repurposing: terminology and definitions in literature
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Sirota, M., Dudley, J. T., Kim, J., Chiang, A. P., Morgan, A. A., Sweet-Cordero, A., Sage, J., & Butte, A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001318 · Cited by 799
Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease
Dudley, J. T., Sirota, M., Shenoy, M., Pai, R. K., Roedder, S., Chiang, A. P., Morgan, A. A., Sarwal, M. M., Pasricha, P. J., & Butte, A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002648 · Cited by 605
Exploiting drug-disease relationships for computational drug repositioning
Dudley, J. T., Deshpande, T., & Butte, A. J. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr013 · Cited by 524
Shifting from the single to the multitarget paradigm in drug discovery
Medina-Franco, J. L., Giulianotti, M. A., Welmaker, G. S., & Houghten, R. A. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.01.008 · Cited by 483
Polypharmacology – Foe or Friend?
Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465
Drug repurposing from an academic perspective
Oprea, T. I., Bauman, J. E., Bologa, C. G., Buranda, T., Chigaev, A., Edwards, B. S., Jarvik, J. W., Gresham, H. D., Haynes, M. K., Hjelle, B., et al. (2011) · Drug Discovery Today: Therapeutic Strategies · doi:10.1016/j.ddstr.2011.10.002 · Cited by 364
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
Sistigu, A., Viaud, S., Chaput, N., Bracci, L., Proietti, E., & Zitvogel, L. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0245-0 · Cited by 305
In silico repositioning of approved drugs for rare and neglected diseases
Ekins, S., Williams, A. J., Krasowski, M. D., & Freundlich, J. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.016 · Cited by 288
Drug repurposing: far beyond new targets for old drugs
Oprea, T. I., & Mestres, J. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9390-1 · Cited by 285
Biosimilars—why terminology matters
Weise, M., Bielsky, M.-C., De Smet, K., Ehmann, F., Ekman, N., Narayanan, G., Heim, H.-K., Heinonen, E., Ho, K., Thorpe, R., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1936 · Cited by 212
In silico drug repositioning – what we need to know
Liu, Z., Fang, H., Reagan, K., Xu, X., Mendrick, D. L., Slikker, W., & Tong, W. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.08.005 · Cited by 183
Network-based drug repositioning
Wu, Z., Wang, Y., & Chen, L. (2013) · Molecular BioSystems · doi:10.1039/c3mb25382a · Cited by 162
Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years
Braun, M. M., Farag-El-Massah, S., Xu, K., & Coté, T. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3160 · Cited by 148
European regulation on orphan medicinal products: 10 years of experience and future perspectives
Westermark, K., Holm, B. B., Söderholm, M., Llinares-Garcia, J., Rivière, F., Aarum, S., Butlen‐Ducuing, F., Tsigkos, S., Wilk-Kachlicka, A., N'Diamoi, C., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3445 · Cited by 145
Siles, S. A., Srinivasan, A., Pierce, C. G., Lopez-Ribot, J. L., & Ramasubramanian, A. K. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00680-13 · Cited by 120
Defining off-label and unlicensed use of medicines for children: Results of a Delphi survey
Neubert, A. C., Wong, I. C. K., Bonifazi, A., Catapano, M., Felisi, M., Baiardi, P., Giaquinto, C., Knibbe, C. A. J., Sturkenboom, M., Ghaleb, M. A., et al. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.09.007 · Cited by 120
Cheng, F., Zhou, Y., Li, J., Li, W., Liu, G., & Tang, Y. (2012) · Molecular BioSystems · doi:10.1039/c2mb25110h · Cited by 115
Allarakhia, M. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s46289 · Cited by 105
The prince and the pauper. A tale of anticancer targeted agents
Dueñas‐González, A., García‐López, P., Herrera, L. A., Medina‐Franco, J. L., González‐Fierro, A., & Candelaria, M. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-82 · Cited by 103
Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs
Bisson, W. H., Cheltsov, A. V., Bruey-Sédano, N., Lin, B., Chen, J., Goldberger, N. E., May, L. T., Christopoulos, A., Dalton, J. T., Sexton, P. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609752104 · Cited by 101
Jin, G., Fu, C., Zhao, H., Cui, K., Chang, J. C., & Wong, S. T. C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2333 · Cited by 99
Drug Repurposing for Gastrointestinal Stromal Tumor
Pessetto, Z. Y., Weir, S. J., Sethi, G., Broward, M. A., & Godwin, A. K. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0968 · Cited by 97
Impact of Pediatric Exclusivity on Drug Labeling and Demonstrations of Efficacy
Wharton, G. T., Murphy, M. D., Avant, D., Goldsmith, J. V., Chai, G., Rodriguez, W. J., & Eisenstein, E. L. (2014) · Pediatrics · doi:10.1542/peds.2013-2987 · Cited by 90
Li, H., Liu, A., Zhao, Z., Xu, Y. F., Lin, J., Jou, D., & Li, C. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101330h · Cited by 87
Recycling side-effects into clinical markers for drug repositioning
Duran‐Frigola, M., & Aloy, P. (2012) · Genome Medicine · doi:10.1186/gm302 · Cited by 50
Drug repurposing in pediatrics and pediatric hematology oncology
Blatt, J., & Corey, S. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.009 · Cited by 48
Nilubol, N., Zhang, L., Shen, M., Zhang, Y., He, M., Austin, C. P., & Kebebew, E. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-198 · Cited by 40
Retrospective clinical analysis for drug rescue: for new indications or stratified patient groups
Cavalla, D., & Singal, C. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.019 · Cited by 33
Southan, C., Williams, A. J., & Ekins, S. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.11.005 · Cited by 25
APT drug R&D: the right active ingredient in the right presentation for the right therapeutic use
Cavalla, D. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2981 · Cited by 22
Stoyanova-Beninska, V. V., Wohlfarth, T. D., Isaac, M., Kalverdijk, L. J., van den Berg, H., & Wied, C. C. G. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.06.011 · Cited by 20
Harland, L., & Gaulton, A. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903049290 · Cited by 16
Treatment-resistant insomnia treated with pregabalin.
Iorio, G. D., Matarazzo, I., Tizio, L. D., et al. (2013) · PubMed · Cited by 10
Cited by
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Drug repositioning: a brief overview
Jourdan, J.-P., Bureau, R., Rochais, C., & Dallemagne, P. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13273 · Cited by 470
“The number of articles devoted to this concept grew exponentially from 2010 onwards,([3]) to reach 602 in 2018 (based on a search of PubMed on November, 21th 2019 for titles or abstracts containing the terms ‘drug repositioning’ or ‘drug repurposing’ and the publication year 2018).”
BackgroundMachine learning approaches and databases for prediction of drug–target interaction: a survey paper
Bagherian, M., Sabeti, E., Wang, K., Sartor, M. A., Nikolovska-Coleska, Z., & Najarian, K. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbz157 · Cited by 429
Drug repurposing for antimicrobial discovery
Farha, M. A., & Brown, E. D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0357-1 · Cited by 360
Drug repositioning and repurposing for Alzheimer disease
Ballard, C., Aarsland, D., Cummings, J., O’Brien, J., Mills, R., Molinuevo, J. L., Fladby, T., Williams, G., Doherty, P., Corbett, A., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0397-4 · Cited by 201
Metadata
- Authors
- Langedijk, J., Mantel-Teeuwisse, A. K., Slijkerman, D. S., & Schutjens, M.-H. D. B.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 20
- Issue
- 8
- Pages
- 1027-1034
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W1737223868
- Cited by
- 323
- References
- 34
- FWCI
- 18.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.